Premium
Protease inhibitors: A panacea?
Author(s) -
Haq Soghra Khatun,
Rabbani Gulam,
Ahmad Ejaz,
Atif Sheikh Muhammad,
Khan Rizwan Hasan
Publication year - 2010
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.20335
Subject(s) - proteases , protease , biology , enzyme , disease , cancer , medicine , biochemistry , genetics
With the increasing evidence of protease involvement in several diseases, novel strategies for drug development involve the use of protease inhibitors (PIs). The local balance between protease inhibitors and proteases is an important determinant of the occurrence and progression of a particular disease. Hence, enzymes and their cognate inhibitors are finding their applications as diagnostic and prognostic markers. PIs are widely implicated for their use in host defense against infection, tissue repair and matrix production, blood coagulation, cancer, and they are, therefore, the current focus as therapeutic alternatives for major diseases such as AIDS and Alzheimer's diseases. This review is a brief summary of the varied role of protein protease inhibitors in controlling the activity of aberrant enzymes in several diseases afflicting mankind today. © 2010 Wiley Periodicals, Inc. J Biochem Mol Toxicol 24:270–277, 2010; View this article online at wileyonlinelibrary.com . DOI 10.1002/jbt.20335